A method for minimising or preventing the induction of stress-related or stress-induced inappetance or inanition in an animal selected for a marketing or management practice.

A layered solid formulation (100a) as one hydrogen supply material (200) according to the present invention includes silicon fine particles having a capability of generating hydrogen and aggregates of the silicon fine particles, and a physiologically acceptable medium (90b) that gets contact with the silicon fine particles or the aggregates thereof. The hydrogen supply material (200) is a hydrogen supply material for bringing the hydrogen into contact with the skin and/or the mucous membrane through the medium (90b).

A layered solid formulation (100a) as one hydrogen supply material (200) according to the present invention includes silicon fine particles having a capability of generating hydrogen and aggregates of the silicon fine particles, and a physiologically acceptable medium (90b) that gets contact with the silicon fine particles or the aggregates thereof. The hydrogen supply material (200) is a hydrogen supply material for bringing the hydrogen into contact with the skin and/or the mucous membrane through the medium (90b).

A layered solid formulation (100a) as one hydrogen supply material (200) according to the present invention includes silicon fine particles having a capability of generating hydrogen and aggregates of the silicon fine particles, and a physiologically acceptable medium (90b) that gets contact with the silicon fine particles or the aggregates thereof. The hydrogen supply material (200) is a hydrogen supply material for bringing the hydrogen into contact with the skin and/or the mucous membrane through the medium (90b).

Nitrous oxide and oxygen for use in treating ARDS caused by viral and bacterial infections, injuries, or other conditions that have resulted in acute, excess activation of the cytokine system in a patient in need thereof is provided. The treatment comprises administering nitrous oxide and oxygen to the patient by inhalation before, during, and/or after ARDS occurs. It is also applicable for treating, alleviating, and/or preventing an aftereffect of said conditions. A composition, duration, an interval, and a total amount of nitrous oxide and oxygen depend on each patient's individual situation and needs. Inhalation of nitrous oxide and oxygen can also stop the post ARDS symptoms that remain after an acute ARDS condition such as, but not limited to viral infections, bacterial infections, injuries, or any condition that results from any cytokine storm. Inhalation of nitrous oxide and oxygen can also treat local cytokine damages caused by said conditions.

Nitrous oxide and oxygen for use in treating ARDS caused by viral and bacterial infections, injuries, or other conditions that have resulted in acute, excess activation of the cytokine system in a patient in need thereof is provided. The treatment comprises administering nitrous oxide and oxygen to the patient by inhalation before, during, and/or after ARDS occurs. It is also applicable for treating, alleviating, and/or preventing an aftereffect of said conditions. A composition, duration, an interval, and a total amount of nitrous oxide and oxygen depend on each patient's individual situation and needs. Inhalation of nitrous oxide and oxygen can also stop the post ARDS symptoms that remain after an acute ARDS condition such as, but not limited to viral infections, bacterial infections, injuries, or any condition that results from any cytokine storm. Inhalation of nitrous oxide and oxygen can also treat local cytokine damages caused by said conditions.

A nutritional supplement provides Vitamin E; sophora flavescens extract; zinc; and at least two ingredients selected from the group consisting of hemp grapeseed extract, hemp curcumin, hemp boswellia, hemp black pepper, hemp magnolia, hemp ginger, hemp oregano leaf, hemp orange peel, hemp methyl sulfano methane (MSM), hemp poplar, hemp chia, hemp meadow sweet, hemp clove powder, hemp cinnamon, and hemp basil (excluding hay basil and hay basil extract). The supplement can be used to reduce joint inflammation, reduce stiffness, reduce lameness, improve flexion, and improve amount of movement and mobility by supporting joint health.

The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ε.sub.ijk equal to or above 200, and an insulator material with a dielectric constant ε.sub.ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.

The present invention concerns a food composition for use in preventing nutrients' inadequacies in lactating women with high saturated fatty acid type dietary patter.

The present invention concerns a food composition for use in preventing nutrients' inadequacies in lactating women with high saturated fatty acid type dietary patter.